J. Lusher

发表

Viral safety and inhibitor development associated with factor VIIIC ultra-purified from plasma in hemophiliacs previously unexposed to factor VIIIC concentrates. The Monoclate Study Group.

J. Lusher, P. Salzman, 1990, Seminars in hematology.

Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors

S. Arkin, J. Lusher, C. Abilgaard, 1993 .

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.

S. Arkin, J. Lusher, R. Schwartz, 1993, The New England journal of medicine.

Viral safety and inhibitor development associated with monoclonal antibody-purified F VIII C

J. Lusher, 1991, Annals of Hematology.

Neurological complications of sickle cell anemia.

J. Lusher, S. Sarnaik, 1982, The American journal of pediatric hematology/oncology.

Periodic transfusions for sickle cell anemia and CNS infarction.

Y. Ravindranath, J. Lusher, S. Sarnaik, 1979, American journal of diseases of children.

Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.

D. Dimichele, G. White, B. Ewenstein, 2000, Haematologica.

Effect of age on human immunodeficiency virus type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders. Transfusion Safety Study Group.

M. Fletcher, J. Parker, J. Lusher, 1992 .

A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group.

P. Mannucci, Y. Laurian, C. Kasper, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors

J. Gill, B. Glader, N. Key, 1998, Thrombosis and Haemostasis.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

D. Bellissimo, R. Hoffmann, C. Leissinger, 2016, Blood.

Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study

A. Tosetto, S. Lethagen, J. Eikenboom, 2006, Journal of thrombosis and haemostasis : JTH.

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA Official Publication of the Scandinavian Association of Obstetricians and Gynaecologists Address: Department of Obstetrics and Gynecology, Sabbatsberg Hospital, S-113 82 Stockholm, Sweden SUPPLEMENT 40 Scanning Electron Microscopy of Human Reproductive P

H. Ludwig, M. Barnhart, J. Lusher, 1975 .

Scanning Electron Microscopy of Human Reproductive Physiology

H. Ludwig, M. Barnhart, J. Lusher, 1975, Acta obstetricia et gynecologica Scandinavica. Supplement.

Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography

I. Warrier, J. Lusher, M. Chitlur, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction

J. Lusher, A. Khalifa, Hushang Haghighat, 1976, American journal of hematology.

Pulmonary embolism-experience at a single children's hospital.

I. Warrier, J. Lusher, M. Chitlur, 2007, Thrombosis research.

Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee

C. Kasper, J. Lusher, J. Lusher, 1993, Transfusion.

Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.

S. Shapiro, P. Levine, A. Rao, 1980, The New England journal of medicine.

Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII

J. Lusher, 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII.

P. Levine, L. Aledort, G. White, 1983, Blood.

Effect of age on human immunodeficiency virus type 1-induced changes in lymphocyte populations among persons with congenital clotting disorders. Transfusion Safety Study Group.

M. Fletcher, J. Parker, J. Lusher, 1992, Blood.

Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions.

J. Gitlin, J. Lusher, S. Sarnaik, 1984, Blood.

THROMBOSIS AND HEMOSTASIS No increase in bleeding identi fi ed in type 1 VWD subjects with D 1472 H sequence variation

R. Hoffmann, C. Leissinger, R. Montgomery, 2013 .

DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease.

J. Lusher, A. Warrier, 1983, The Journal of pediatrics.

Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance

M. Epstein, K. Lewis, C. Kempton, 2013, PloS one.

First and Second Generation Recombinant Factor VIII Concentrates in Previously Untreated Patients: Recovery, Safety, Efficacy, and Inhibitor Development

J. Lusher, 2002, Seminars in thrombosis and hemostasis.

Definitions in Hemophilia

F. Rosendaal, C. Rothschild, L. Aledort, 2001, Thrombosis and Haemostasis.

Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors

I. Warrier, J. Lusher, J. Lusher, 2000, Haemophilia : the official journal of the World Federation of Hemophilia.

Standardization of thromboelastography: values and challenges.

J. Lusher, M. Chitlur, 2010, Seminars in thrombosis and hemostasis.

The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A

C. Kessler, C. Bedrosian, C. Lee, 2003 .

Congenital Disorders Affecting Platelets

M. Barnhart, J. Lusher, 2008, Seminars in thrombosis and hemostasis.

Evolution of recombinant factor VIII safety: KOGENATE® and Kogenate® FS/Bayer

I. Scharrer, J. Lusher, 2009, International journal of hematology.

Is the incidence and prevalence of inhibitors greater with recombinant products? No

J. Lusher, J. Lusher, 2004, Journal of thrombosis and haemostasis : JTH.

Inhibitor Antibodies to Factor VIII and Factor IX: Management

J. Lusher, 2000, Seminars in thrombosis and hemostasis.

Infections in leukemic children: a prospective analysis.

Y. Ravindranath, J. Lusher, T. Shope, 1980, The Journal of pediatrics.

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa

W. T. Sawyer, C. Lindley, J. Lusher, 1994, Clinical pharmacology and therapeutics.

Recombinant Clotting Factors

J. Lusher, 2000, BioDrugs.

Inhibitors in young boys with haemophilia.

J. Lusher, 2000, Bailliere's best practice & research. Clinical haematology.

6 Recombinant clotting factor concentrates

J. Lusher, 1996 .

Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a Phase I study

A. Bloom, C. Lindley, J. Lusher, 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature.

J. Lusher, R. Kulkarni, 1999, Journal of pediatric hematology/oncology.

The Hematological Aspects of a Case of Systemic Lupus Erythematosus

J. Lusher, A. Robson, L. Kahn, 1968, Clinical pediatrics.

clotting disorders. Transfusion Safety Study Group changes in lymphocyte populations among persons with congenital Effect of age on human immunodeficiency virus type 1-induced

M. Fletcher, J. Parker, J. Lusher, 2011 .

Hemophilia A in chromosomal female subjects.

J. Lusher, W. Zuelzer, R. K. Evans, 1969, The Journal of pediatrics.

Inhibitors to Coagulation Factors

L. Aledort, G. White, J. Lusher, 1995, Advances in Experimental Medicine and Biology.

Antibody nature of an AHG (Factor VIII)inhibitor

J. Lusher, J. Shuster, R. K. Evans, 1968 .

Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis

C. Kessler, R. Montgomery, J. Gill, 1996, British journal of haematology.

The human spleen as revealed by scanning electron microscopy

M. Barnhart, J. Lusher, 1976, American journal of hematology.

Essential thrombocythemia in a child: Platelet ultrastructure and function

M. Barnhart, B. Evatt, J. Lusher, 1980, American journal of hematology.

The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.

C. Kessler, J. Lusher, G. Pierce, 1989, JAMA.

The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.

D. Brettler, A. Forsberg, P. Levine, 1989, Archives of internal medicine.

Sickle cell crisis terminated by intravenous urea in sugar solutions—a preliminary report

J. Lusher, R. Henry, Jerry W. Anderson, 1971, The American journal of the medical sciences.

PLATELET‐VESSEL‐WALL INTERACTIONS: EXPERIENCES WITH VON WILLEBRAND PLATELETS *

M. Barnhart, J. Lusher, R. Wilkins, 1981, Annals of the New York Academy of Sciences.

dDAVP in von Willebrand’s Disease and in Moderately Severe Hemophilia A

J. Lusher, A. Warrier, 1984 .

DDAVP: does the drug have a direct effect on the vessel wall?

M. Barnhart, J. Lusher, S. Chen, 1983, Thrombosis research.

DDAVP: DOES TEE DRUG RAVE A DIRECT EFFECT ON TEE VESSEL WALL?

M. Barnhart, J. Lusher, K. Brinkhous, 1983 .

SEVERE FACTOR VIII AND FACTOR IX DEFICIENCY IN FEMALES: 629

C. Mcmillan, J. Lusher, C. McMillan, 1978 .

Prediction and management of adverse events associated with the use of factor IX complex concentrates.

J. Lusher, 1993, Seminars in hematology.

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

D. Bellissimo, C. Leissinger, R. Montgomery, 2012, Blood.

Fibrinolytic parameters in children with noncatheter thrombosis: a pilot study

I. Warrier, J. Lusher, M. Chitlur, 2010, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Summary of clinical experience with recombinant factor VIII products — Kogenate

J. Lusher, 2005, Annals of Hematology.

F, Spiro I: Posttransplantation lymphoproliferative disorders in solid Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B

I. Warrier, P. Saidi, J. Lusher, 1997 .

Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors.

J. Lusher, 1996, Haemostasis.

Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors--benefits and limitations.

J. Lusher, Jeanne M. Lusher, 1994, Seminars in hematology.

Factor VIII and IX Inhibitors in Hemophilia

J. Lusher, M. Chitlur, 2014 .

Chromosome Studies The May-Hegglin Anomaly: Platelet Function, Ultrastructure and

J. Lusher, R. K. Evans, J. Schneider, 2011 .

The May-Hegglin anomaly: platelet function, ultrastructure and chromosome studies.

J. Lusher, R. K. Evans, J. Schneider, 1968, Blood.

Acute lymphoid leukemia.

Y. Ravindranath, J. Lusher, 1978, Pediatric annals.

Controlled clinical trials with prothrombin complex concentrates.

J. Lusher, 1984, Progress in clinical and biological research.

Prophylactic therapy with Fibrogammin® P is associated with a decreased incidence of bleeding episodes: a retrospective study

S. Alexander, S. Pipe, J. Lusher, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Myocardial Infarction and Stroke-is the Risk Increased by Desmopressin?

J. Lusher, 1993 .

Pharmacology and Pharmacokinetics of Desmopressin in Haemostatic Disorders

J. Lusher, 1990 .

Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection

J. Lusher, U. Thisyakorn, P. Seksarn, 2005, Thrombosis and Haemostasis.

North American study of factor VIII concentrate potency.

F. Ofosu, J. Lusher, S. Chavin, 2009, Scandinavian journal of haematology. Supplementum.

Antibody nature of an AHG inhibitor (Factor VIII)

J. Lusher, J. Shuster, R. K. Evans, 1968 .

Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia.

D. Ginsburg, K. High, J. Lusher, 2000, Hematology. American Society of Hematology. Education Program.

Considerations for current and future management of haemophilia and its complications

J. Lusher, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Thrombogenicity associated with factor IX complex concentrates.

J. Lusher, J M Lusher, 1991, Seminars in hematology.

The role of prothrombin complex concentrates in the treatment of hemophiliacs with factor VIII inhibitors.

J. Lusher, 2009, Scandinavian journal of haematology. Supplementum.

Early treatment with recombinant factor VIIa results in greater efficacy with less product

J. Lusher, 1998, European journal of haematology. Supplementum.

Recombinant activated factor VII for treatment of intramuscular haemorrhages: a comparison of early versus late treatment.

J. Lusher, 1998, Blood Coagulation and Fibrinolysis.

A longer acting rFVIII, safe and effective.

J. Lusher, 2014, Blood.

Thromboelastography in children with coagulation factor deficiencies

I. Warrier, J. Lusher, M. Chitlur, 2008, British journal of haematology.

Thromboelastography in children with coagulation factor

I. Warrier, J. Lusher, M. Chitlur, 2008 .

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

V. Blanchette, C. Rothschild, C. Négrier, 2005, Blood.

Kogenate® FS: antihemophilic factor rFVIII-FS

J. Lusher, M. Chitlur, 2006 .

Emergency department visits in children with hemophilia

M. Callaghan, J. Lusher, A. Zia, 2013, Pediatric blood & cancer.

Clinical Trials of Recombinant Factor VIII

P. Mannucci, C. Kessler, H. Kingdon, 1991 .

construct administered by peripheral intravenous infusion Phase I trial of FVIII gene transfer for severe hemophilia A using a retroviral

E. Tom, H. Roehl, M. Ragni, 2013 .

retroviral construct administered by peripheral intravenous infusion Phase 1 trial of FVIII gene transfer for severe hemophilia A using a

H. Roehl, M. Ragni, G. White, 2013 .

Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion.

H. Roehl, M. Ragni, G. White, 2003, Blood.

Prophylaxis in Children with Hemophilia: Is it the Optimal Treatment?

J. Lusher, 1997, Thrombosis and Haemostasis.

Perinatal management of newborns with haemophilia

J. Lusher, R. Kulkarni, 2001, British journal of haematology.

Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.

M. Hannan, A. Shapiro, M. Ragni, 1996, Thrombosis and Haemostasis.

Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status

C. Kessler, D. Brettler, L. Aledort, 1993, The Lancet.

Determining the Sensitivity of Coagulation Screening Reagents: A Simplified Method

J. Lusher, C. Hillman, 1982 .

Clinical experience with recombinant factor VIIa.

J. Lusher, H. Roberts, U. Hedner, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Open heart surgery in a hemophiliac patient. Hematologic management.

Y. Ravindranath, J. Lusher, E. Green, 1974, American journal of diseases of children.

How do you treat bleeding disorders with desmopressin?

J. Lusher, M. Rajpurkar, Bülent Özgönenel, 2007, Postgraduate Medical Journal.

Management of patients with factor VIII inhibitors.

J. Lusher, 1987, Transfusion medicine reviews.

Pediatric REFERENCE Values for Molecular Markers in Hemostasis

J. Lusher, P. Seksarn, D. Sosothikul, 2007, Journal of pediatric hematology/oncology.

Screening and diagnosis of coagulation disorders.

J. Lusher, 1996, American journal of obstetrics and gynecology.

Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: A White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA

K. Ponder, J. Soucie, W. Hoots, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A

C. Rothschild, J. Gill, P. Larson, 2005, Thrombosis and Haemostasis.

Human recombinant DNA‐derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation

P. Mannucci, S. Arkin, R. Zimmermann, 2004, Journal of thrombosis and haemostasis : JTH.

Hemophilia and von Willebrand's disease in the 1990s : a new decade of hopes and challenges : proceedings of the XIX Congress of the World Federation of Hemophilia, Washington, D.C., 14-19 August 1990

C. Kessler, J. Lusher, 1991 .

Viral contamination of blood products

B. Colvin, Y. Laurian, J. Lusher, 1994, The Lancet.

Comment on Mahlangu Et Al, Page 317

J. Lusher, 2022 .

Natural History of Inhibitors in Severe Haemophilia A and B: Incidence and Prevalence

J. Lusher, 2008 .

Protocols, Dosages and Clinical Aspects of Immune Tolerance

G. Mariani, J. Lusher, 1996, Vox sanguinis.

Factor VIII Inhibitors

J. Lusher, 1987, Annals of the New York Academy of Sciences.

Development and introduction of recombinant factor VIII – a clinician’s experience

J. Lusher, J. Lusher, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

High‐titer inhibitor development in hemophilia A: lack of product specificity

J. Lusher, W. Hoots, 2004, Journal of thrombosis and haemostasis : JTH.

HIV and hemophilia

J. Lusher, A. Brownstein, 2007 .

Recombinant clotting factor concentrates.

J. Lusher, 1996, Bailliere's clinical haematology.

Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial.

S. Shapiro, P. Levine, A. Rao, 1980, Transactions of the Association of American Physicians.

Inhibitor Development in Prospective Clinical Trials with Recombinant Factor VIII Preparations in Previously Untreated Patients

J. Lusher, 1999, Vox Sanguinis.

The problem of therapeutic equivalence with paired qualitative data: an example from a clinical trial using haemophiliacs with an inhibitor to factor VIII.

J. Lusher, M. L. Lee, 1991, Statistics in medicine.

Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition.

J. Lusher, 1991, The American journal of medicine.

Development of anaphylactic shock in haemophilia B patients with inhibitors.

I. Warrier, J. Lusher, 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.

J. Lusher, 2000, Haematologica.

Antibody nature of an AHG (factor 8) inhibitor.

J. Lusher, J. Shuster, R. K. Evans, 1968, The Journal of pediatrics.

In vivo recovery with products of very high purity — assay discrepancies

C. Kessler, U. Martinowitz, C. Lee, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

New leukemia in the course of therapy of acute lymphoblastic leukemia

Y. Ravindranath, J. Lusher, W. Zuelzer, 1978, American journal of hematology.

Response to 1-deamino-8-D-arginine vasopressin in von Willebrand disease.

J. Lusher, 1994, Haemostasis.

Transfusion therapy in congenital coagulopathies.

J. Lusher, 1994, Hematology/oncology clinics of North America.

PLASMA FVIII LEVELS MEASURED AFTER INFUSION OF RECOMBINANT F VIII (rFVIII) VARY SIGNIFICANTLY WITH DIFFERENT ASSAY METHODS - (WILL THE REAL FVIII LEVEL PLEASE STAND UP!). † 934

J. Lusher, D. Hurst, P. Simpson, 1996, Pediatric Research.

Development of Disease-Specific Health-Related Quality-of-Life Instruments for Children With Immune Thrombocytopenic Purpura and Their Parents

D. Feeny, J. Bussel, V. Blanchette, 2003, Journal of pediatric hematology/oncology.

Milestones in hemophilia and concepts in future clinical trial design.

J. Lusher, 2006, Seminars in hematology.

Gene therapy for hemophilia A and B: patient selection and follow-up, requirements for a cure.

J. Lusher, 1999, Thrombosis and haemostasis.

Treatment of hemophilia: plasma-derived clotting factors

J. Lusher, M. Chitlur, 2014 .

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

R. Hoffmann, C. Leissinger, P. Morateck, 2010, Blood.

The Prevalence of Reduced VWF Survival Phenotype (Type 1C VWD) in Type 1 Index Cases Recruited into the TS Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB - VWD).

D. Bellissimo, C. Leissinger, R. Montgomery, 2007 .

Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing.

D. Bellissimo, C. Leissinger, R. Montgomery, 2007 .

Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates 1

C. Pegelow, E. Operskalski, M. Hilgartner, 1990, Vox sanguinis.

Management of Factor VIII and Factor IX Inhibitors

J. Lusher, 1991 .

Intravenous gamma globulin treatment for chronic idiopathic thrombocytopenic purpura in children.

I. Warrier, J. Lusher, 1984, The American journal of medicine.

Low CD4+ counts in a study of transfusion safety. The Transfusion Safety Study Group.

E. Operskalski, L. Aledort, J. Lusher, 1993, The New England journal of medicine.

Arteriovenous shunts in the human spleen

M. Barnhart, J. Lusher, C. Baechler, 1976, American journal of hematology.

Effect of therapy on the serum level of alpha-1 fetoprotein in embryonal cell carcinoma.

J. Lusher, K. Kithier, M. D. Poulik, 1972, The Journal of pediatrics.

National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C

Eugene R. Schiff, William H. Hall, W. H. Hall, 1997, Hepatology.

Erythropoiesis in sickle cell anaemia during acute infection and crisis.

J. Lusher, T. Haddy, S. Hendricks, 2009, Scandinavian journal of haematology.

Idiopathic thrombocytopenic purpura in childhood.

J. Lusher, W. Zuelzer, Wolf W. Zuelzer, 1966, The Journal of pediatrics.

Dithionite tube test--a rapid, inexpensive technique for the detection of hemoglobin S and non-S sickling hemoglobin.

P. Wolf, J. Lusher, R. Nalbandian, 1971, Clinical chemistry.

Automated dithionite test for rapid, inexpensive detection of hemoglobin S and non-S sickling hemoglobinopathies.

P. Wolf, J. Lusher, R. Nalbandian, 1971, Clinical chemistry.

Systemic causes of excessive uterine bleeding.

J. Lusher, 1999, Seminars in hematology.

Preoperative exchange transfusion in sickle cell anemia.

J. Lusher, S. Sarnaik, A. Philippart, 1981, Journal of pediatric surgery.

the VWF activity assay by ristocetin cofactor Common VWF exon 28 polymorphisms in African Americans affecting

R. Hoffmann, C. Leissinger, P. Morateck, 2012 .

Sickledex test for hemoglobin S. A critique.

J. Lusher, R. Nalbandian, F. Camp, 1971, JAMA.

Long-term survivors of acute lymphoblastic leukemia--risk of relapse after cessation of therapy.

Y. Ravindranath, J. Lusher, D. Soorya, 1981, Medical and pediatric oncology.

Exchange transfusion for hyperleukocytosis, anemia, and metabolic abnormalities in leukemia.

Y. Ravindranath, A. Emami, J. Lusher, 1981, The Journal of pediatrics.

Use of intravenous gamma globulin in children and adolescents with idiopathic thrombocytopenic purpura and other immune thrombocytopenias.

I. Warrier, J. Lusher, 1987, The American journal of medicine.

Accurate prenatal diagnosis with novel polymerase chain reaction primers in a family with sporadic hemophilia A.

S. Kogan, M. Evans, J. Lusher, 1989, Obstetrics and gynecology.

Childhood Idiopathic Thrombocytopenic Purpura: To Treat or Not To Treat

J. Lusher, W. Zuelzer, 1977 .

Coagulopathies and pediatric stroke

J. Lusher, M. Rajpurkar, 2010, Journal of Pediatric Neurology.

The effect of 5-hydroxytryptamine and epinephrine on newborn platelets

J. Lusher, M. Alebouyeh, M. Ameri, 1978, European Journal of Pediatrics.

Factor VIII concentrates: matching what you see with what you get.

J. Lusher, 1985, JAMA.

Primary malignant lymphoma cutis in an infant: case report and review of literature.

Y. Ravindranath, J. Lusher, P. Bhanot, 1979, Pediatrics.

Acute idiopathic thrombocytopenic purpura--management in childhood.

S. Feig, C. Moertel, B. Glader, 1997, Blood.

Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group.

M. Pike, M. Hilgartner, L. Aledort, 1992, BMJ.

Oral urea and the prophylactic treatment of sickle cell disease—a preliminary report

J. Lusher, R. Henry, Jerry W. Anderson, 1971, The American journal of the medical sciences.

Second malignancy in acute lymphocytic leukemia.

Y. Ravindranath, J. Lusher, S. Inoue, 1982, American journal of diseases of children.

Recombinant Factor VIIa

J. Lusher, 1999, BioDrugs.

Absence of inhibitory cells from patients with aplastic anemia or transient erythroblastopenia of childhood on the in vitro growth of erythroid colonies.

Y. Ravindranath, J. Lusher, S. Inoue, 1980, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.

Factor VIII inhibitors with recombinant products : prospective clinical trials. Discussion

J. Lusher, Aledort, Lusher, 2000 .

Transmission of hepatitis C virus by monoclonal-purified viral-attenuated factor VIII concentrate

D. Brettler, J. Lusher, G. Bergman, 1995, The Lancet.

CHLOROMA AS A PRESENTING FEATURE OF ACUTE LEUKEMIA. A REPORT OF TWO CASES IN CHILDREN.

J. Lusher, 1964, American journal of diseases of children.

Increase in Leu 2+ Leu 7+ lymphocytes in HIV 1-seropositive patients with hemophilia repeatedly treated with clotting factor concentrates.

J. Lusher, J. Kaplan, I. Sarnaik, 1988, Clinical immunology and immunopathology.

URACIL MUSTARY THERAPY IN METASTATIC WILMS'S TUMOR.

J. Lusher, T. Vietti, D. Berry, 1964, American journal of diseases of children.

Characterization of autoantibodies against the platelet glycoprotein antigens llb/llla in childhood idiopathic thrombocytopenia purpura

J. Taub, I. Warrier, J. Lusher, 1995, American journal of hematology.

Use of a Highly Concentrated Intranasal Spray Formulation of Desmopressin in Persons with Congenital Bleeding Disorders

I. Warrier, J. Lusher, E. Miller, 1993 .

Risk of human immunodeficiency virus type 1 infection among sexual and nonsexual household contacts of persons with congenital clotting disorders.

C. Pegelow, E. Operskalski, M. Hilgartner, 1991, Pediatrics.

Plasma Homocysteine Levels, Methylene Tetrahydrofolate Reductase Polymorphisms, and the Risk of Thromboembolism in Children

Y. Ravindranath, J. Lusher, M. Chitlur, 2011, Journal of pediatric hematology/oncology.

A community-based partnership to promote information infrastructure for bleeding disorders.

D. Aschman, A. Forsberg, A. Shapiro, 2011, American journal of preventive medicine.

Human antibodies to recombinant factor VII in hemophiliacs.

J. Lusher, 1994, Journal of interferon research.

Idiopathic Thrombocytopenic Purpura in Children

J. Lusher, R. Iyer, 1977, Seminars in thrombosis and hemostasis.

Childhood idiopathic thrombocytopenic purpura.

J. Lusher, W. Zuelzer, 1977, American journal of diseases of children.

Idiopathic thrombocytopenic purpura in children. The case for management without corticosteroids.

Y. Ravindranath, A. Emami, J. Lusher, 1984, The American journal of pediatric hematology/oncology.

Intravenous gammaglobulin (Gamimune) for treatment of chronic idiopathic thrombocytopenic purpura (ITP): A two‐year follow‐up

I. Warrier, J. Lusher, 1986 .

Decreased clearance of von Willebrand factor in a patient with type 2B von Willebrand disease following development of immune thrombocytopenia

M. Callaghan, J. Lusher, M. Chitlur, 2008, Pediatric blood & cancer.

629 SEVERE FACTOR VIII AND FACTOR IX DEFICIENCY IN FEMALES

C. Mcmillan, J. Lusher, C. McMillan, 1978, Pediatric Research.

Macroglobulinemia in a child with acute leukemia.

J. Lusher, W. Zuelzer, J. Čejka, 1974, Blood.

IMFRA (Intermittent Intrathecal Methotrexate and Fractional Radiation) plus chemotherapy in childhood leukemia

Y. Ravindranath, J. Lusher, S. Sarnaik, 1976, American journal of hematology.

Lack of inhibitor to monoclonal-antibody purified factor VIII concentrate

J. Lusher, 1990, The Lancet.

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

R. Hoffmann, C. Leissinger, R. Montgomery, 2013, Blood.

Hemophilia: continued challenges but reason for optimism on many fronts

J. Lusher, 1993, Transfusion.

Anti‐s Hemolytic Disease: A Case Report

J. Lusher, W. Zuelzer, P. Parsons, 1966, Transfusion.

A randomized, double‐blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors

Shapiro, Kasper, Y. Laurian, 1998 .

Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group.

P. Mannucci, D. Brettler, M. Hilgartner, 1990, The New England journal of medicine.

Evaluation of oral urea in the management of sickle cell anemia.

M. Barnhart, J. Lusher, 1972, Advances in Experimental Medicine and Biology.

Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001–2003

J. Goedert, M. Lederman, J. Goedert, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group.

P. Mannucci, D. Brettler, N. Ciavarella, 1990, Annals of internal medicine.

The overall effectiveness of prophylaxis in severe haemophilia

I. Warrier, J. Lusher, J. Lusher, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII

P. Mannucci, B. Hayward, M. Recht, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Central Nervous System Prophylaxis with Intermittent Intrathecal Methotrexate and Fractional Radiation in Childhood Acute Lymphoblastic Leukemia

Y. Ravindranath, I. Warrier, J. Lusher, 1983 .

Repetitive low-dose radiation therapy for acute stem-cell leukemia.

Y. Ravindranath, J. Lusher, W. Zuelzer, 1977, International Journal of Radiation Oncology, Biology, Physics.

Testicular relapse (TR) in childhood acute lymphoblastic leukemia (ALL)

Y. Ravindranath, J. Lusher, 1979 .

Thromboelastography identifies children with rare bleeding disorders and predicts bleeding phenotype

M. Callaghan, J. Lusher, J. Lusher, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

IMMUNOLOGIC TOLERANCE OF ABO INCOMPATIBLE ERYTHROCYTES IN HUMAN NEONATES.

J. Lusher, M. Copper, 1964, The Journal of pediatrics.

Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease

R. Watts, E. Kraut, B. Kerlin, 2009, Haemophilia.

Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project

J. Gill, B. Evatt, J. Soucie, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Idiopathic Thrombocytopenic Purpura in Children

J. Lusher, R. Iyer, 1977, Seminars in thrombosis and hemostasis.

Effect of therapy on the serum level of alpha-1/etoprotein

J. Lusher, K. Kithier, M. D. Poulik, 1972 .